Redeye concludes that the figures in Physitrack’s Q3 2023 report were generally in line with our estimates. Revenue growth of 14% paired with limited cost base expansion derived long-awaited margin improvements. In addition, the cash flow improved q/q along with the ARR. Consequently, we anticipate minor adjustments to our near-term estimates and fair value range.